ACVR2A Knockout HAP1 Cell Line

ACVR2A and ACVR2B are the two type II activin receptors — serine/threonine kinase receptors that bind activins, myostatin (GDF8), GDF11, BMPs, and other TGF-β superfamily ligands; upon ligand binding, the type II receptor recruits and phosphorylates type I receptors (ALK4/ACVR1B, ALK5, ALK7), which then phosphorylate SMAD2/3 (activin/myostatin branch) to regulate gene expression. ACVR2A and ACVR2B share substantial ligand and functional overlap, with myostatin/GDF11-mediated muscle growth suppression being a major shared function. This ligand-trap axis is the basis of several clinically important therapeutics. The choice between knockout and overexpression depends on whether you are studying ACVR2A in the HAP1 haploid platform for systematic genetic analysis. This ACVR2A Knockout in HAP1 enables study of ACVR2A-specific functions in a clean haploid background. Overexpression is useful for studying ACVR2A gain-of-function effects. Important consideration: ACVR2B paralog expression analysis aids interpretation given substantial functional overlap. This product complements the parallel ACVR2A Knockout in HEK293 and the ACVR2A & ACVR2B Double Knockout in HEK293 (both also available) for systematic cross-background paralog dissection. Rescue with wild-type or kinase-dead ACVR2A is the standard specificity control. The knockout is valuable for studying activin/myostatin type II receptor biology and as a specificity tool for sotatercept/luspatercept/bimagrumab-class ligand traps. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

Primary applications: • Haploid genetic analysis: ACVR2A-null phenotypes in HAP1's clean genetic background. • ACVR2A/2B paralog dissection: parallel analysis with ACVR2A KO in HEK293 and the double KO (both available) for systematic cross-background studies. • SMAD2/3 signaling: activin/myostatin-induced phospho-SMAD2/3 analysis. • Ligand trap specificity: complementary genetic control for sotatercept/luspatercept/bimagrumab. EDITGENE recommends this HAP1-based model complementary to the HEK293 products for systematic ACVR2A paralog dissection.

Yes. ACVR2A rescue in HAP1 follows the same considerations as the HEK293 product: • Construct design: same considerations as ACVR2A/HEK293 rescue (kinase domain preservation, intracellular C-terminal tag, surface localization validation). • Kinase-dead rescue: K219R mutation abolishes catalytic activity. • Cross-background validation: parallel rescue in HAP1 and HEK293 confirms ACVR2A-specific phenotypes. • Functional readout: rescue should restore activin/myostatin-induced phospho-SMAD2/3. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.